USS Investment Management Ltd lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 30.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,430 shares of the life sciences company's stock after selling 16,563 shares during the quarter. USS Investment Management Ltd's holdings in Illumina were worth $5,003,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Vident Advisory LLC lifted its position in shares of Illumina by 1,269.2% during the 4th quarter. Vident Advisory LLC now owns 99,348 shares of the life sciences company's stock valued at $13,276,000 after buying an additional 92,092 shares during the last quarter. Spyglass Capital Management LLC bought a new stake in Illumina in the 4th quarter valued at about $71,855,000. Triglav Skladi D.O.O. purchased a new stake in Illumina during the fourth quarter valued at about $1,403,000. Taconic Capital Advisors LP purchased a new stake in Illumina during the fourth quarter valued at about $668,000. Finally, Tidal Investments LLC boosted its position in Illumina by 740.3% during the fourth quarter. Tidal Investments LLC now owns 37,385 shares of the life sciences company's stock worth $4,996,000 after purchasing an additional 32,936 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Price Performance
Shares of Illumina stock traded up $1.76 on Tuesday, hitting $82.13. 1,282,325 shares of the company traded hands, compared to its average volume of 2,436,063. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $13.00 billion, a P/E ratio of -10.69, a P/E/G ratio of 1.60 and a beta of 1.35. The firm's 50-day simple moving average is $78.04 and its 200 day simple moving average is $107.89.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter in the prior year, the firm earned $0.98 earnings per share. The firm's revenue was down 1.4% on a year-over-year basis. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ILMN has been the topic of a number of recent research reports. Robert W. Baird dropped their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. reduced their price target on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Stephens reiterated an "overweight" rating and set a $105.00 price objective on shares of Illumina in a research note on Tuesday, May 20th. Finally, Guggenheim cut their target price on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $128.15.
Read Our Latest Report on ILMN
Insiders Place Their Bets
In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the business's stock in a transaction dated Monday, May 12th. The stock was bought at an average price of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer now owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is owned by insiders.
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
